cutaneous T cell lymphoma
Brentuximab Vedotin Beats Standard of Care for CTCL
The CD30-targeted antibody–drug conjugate brentuximab vedotin (BV) was far more active than current ...
MARCH 15, 2017

Load more
The CD30-targeted antibody–drug conjugate brentuximab vedotin (BV) was far more active than current ...
MARCH 15, 2017